Presented by: Zachary V. Fagiani, Associate Scientist, Dragonfly Therapeutics
Abstract: Fc gamma receptor (FcγR) binding is a critical component of ADCC, ADCP, and CDC and an important feature to measure in Fc-containing drugs. The purpose of our study was to determine if testing IgG drugs against a full panel of biotinylated FcγRs can be completed on Carterra’s LSAXTinstrument with higher throughput than a traditional 8-channel biosensor while maintaining equivalent data quality. Our results show that the LSAXT demonstrates highly comparable data relative to the traditional 8-channel biosensor while using 7.5 times less analyte, 6 fewer hours of analyst time, ~$3,000 less in consumables, and producing 8 times as many replicates.
To download the rest of the resource, please fill out the short form below. Thank you.